August 1, 2022
Alliance A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests
Overview: Alliance investigator Marie E. Wood, MD (University of Colorado) leads this study that collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the labora
July 15, 2022
Alliance A032101: A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (mHSPC): A-DREAM
Overview: Atish Choudhury, MD, PhD, of the Dana-Farber Cancer Institute, leads this phase II trial that examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate can
July 14, 2022
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, according to research from The University of Texas MD Anderson Cancer Center published today in JAMA Oncology.
The multicenter, randomized p
